Cited by 98Immune responses and vaccinationsImmunotherapy and Immune ResponsesBacterial Infections and Vaccines

Booster vaccination in the elderly: Their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers

Kaml, Maria, Weiskirchner, Ilka, Keller, Michael, Luft, Thomas, Hoster, Eva, Hasford, Joerg, Young, Linda, Bartlett, Bill +5 more·2006·Vaccine

Abstract

Background Recent retrospective studies demonstrate that elderly persons have a shortened protection period following vaccination with recall antigens.Methods We now analysed the effect of booster vaccination with a multivalent vaccine containing tetanus, dipththeria, pertussis and polio antigens in 252 healthy elderly persons. The magnitude of the humoral immune response was assessed by antibody measurements.Results Comparison with a small control group of 21 younger persons demonstrates that pre- and post-vaccination antibody concentrations are lower in elderly persons for all antigens except polio, for which higher pre- and similar post-vaccination antibody levels are observed. Using multiple linear regression analysis we also show that the magnitude of the humoral immune response in elderly persons greatly depends on pre-vaccination antibody concentrations in the case of tetanus, diphtheria and pertussis, but much less so in the case of polio, against which priming and preceding booster immunizations were performed with attenuated live vaccine.Conclusion Regular booster vaccinations throughout life are of clinical importance to maintain the ability to respond to recall antigens in old age. Longer lasting protection and good responsiveness to boosting in spite of low antibody titres can be expected following exposure to live vaccine earlier in life.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2006.06.037

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The immune system changes with age in nearly every aspect, generally leading to weaker pathogen immunity.

    “The immune system changes with age in nearly every aspect, generally resulting in a decline in pathogen immunity with increased age.”

    From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [5]

  • Ageing is associated with high morbidity and mortality from various infections and with substantially lower vaccine efficacy.

    “ageing is associated with high morbidity and mortality rates for various infections and significant reductions in vaccine efficacy1-6”

    From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [5]

  • Pertussis is relevant for older age groups and does not solely affect infants.

    “Epidemiological data show that pertussis is relevant for older age groups and does not solely affect infants [177].”
  • Immunogenicity of pertussis vaccine is lower in the elderly compared with younger adults.

    “Immunogenicity of the vaccine is lower in the elderly compared with that in younger adults [177].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kaml, M., Weiskirchner, I., Keller, M., Luft, T., Hoster, E., Hasford, J., Young, L., Bartlett, B., Neuner, C., Fischer, K.-H., Neuman, B., Würzner, R., & Grubeck-Loebenstein, B.
Affiliations
  • Austrian Academy of Sciences (AT)
  • Ludwig-Maximilians-Universität München (DE)
  • Sanofi (Canada) (CA)
  • Sanofi (United States) (US)
  • Innsbruck Medical University (AT)
Venue
Vaccine
Publisher
Elsevier BV
Published
2006-11
Volume
24
Issue
47-48
Pages
6808-6811
ISSN
0264-410X (ISSN-L)
OpenAlex
W2085713763
Cited by
98
References
13
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 7 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 9 · 2016: 10 · 2015: 1 · 2014: 3 · 2013: 6 · 2012: 5
FWCI
2.40
Type
journal article
Language
en
Open access
closed
Locations
  • Vaccine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Sanofi Pasteur
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords
booster vaccination, older adults, humoral immune response, antibody titers, recall antigens, live attenuated vaccine, vaccine priming, immunosenescence, vaccine protection duration
MeSH terms
Adult, Aged, Antibodies, Antibody Formation, Female, Humans, Immunization, Secondary, Male, Poliovirus Vaccine, Inactivated, Regression Analysis, Vaccines, Cohort Studies, Diphtheria-Tetanus-Pertussis Vaccine, Vaccines, Conjugate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review